Skip to content

Research to hematopoiesis and immune reconstruction after reduced-intensity conditioning HLA-haploidentical high dose peripheral blood hematopoietic stem cell transplantation

Research to hematopoiesis and immune reconstruction after reduced-intensity conditioning HLA-haploidentical high dose peripheral blood hematopoietic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009421
Enrollment
Unknown
Registered
2016-10-15
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignance

Interventions

Hematopoietic stem cell transplantation group:Reduced-intensity conditioning regimen related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem cell transplantation

Sponsors

Hematologic disease center,First Affiliated Hospital of XinJiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 50 to 65 years old with hematologic malignancies; 2. Patients who is below 50 years old have the fellowing situtation: 1) Patients have an urgent need for transplantation, but with uncured infection. Exp. Patiens have Tuberculosis with residual lesions after anti-TB treatment at 6-9 months, or with standard anti-TB treatment over 3 months; Patiens have remaining infection lesions after infection of bacterial and fungal but stable condition; 2) Organ disfunction: Patients have cardiovascular, respiratory system disease, and dysfunction of liver and kidney who is evaluated to tolerated to RIC-RHNT-PBSCT; 3) Patients can not received MAC transplantation whose bodies are also weaker for some reason.

Exclusion criteria

Exclusion criteria: 1. Patient who is over 65 years old; 2. Patients who suffer uncontrollable infection; 3. Patiens with severe cardiovascular,respiratory system disease and dysfunction of liver and kidney; 4. Patients with mental disease; 5. Patients who refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Engraft rate;Acute graft versus host disease;The cumulative incidence of infection;Costimulatory molecules;Basic immunologic function;

Secondary

MeasureTime frame
Chronic graft versus host disease;Overall Surviver;Disease free survival;Transplantation related mortality;Relapse rate;

Countries

China

Contacts

Public ContactMing Jiang

Hematologic disease center, First Affiliated Hospital of Xinjiang Medical University

jiangmingyy@126.com+86 13609910116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026